Oncology News | pharmaphorum

News

As year-end nears, pharma groups plump up their pipelines

Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

Enhertu moves into frontline breast cancer treatment

Daiichi Sankyo and AstraZeneca's Enhertu has become the first new first-line option in the US for HER2-positive breast cancer in more than a decade.

News

J&J claims FDA's latest national priority voucher

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

SanegeneBio raises $110m for RNAi, plus other financings

Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

News

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer.

As year-end nears, pharma groups plump up their pipelines

Padcev/Keytruda scores again in early bladder cancer

Enhertu moves into frontline breast cancer treatment

J&J claims FDA's latest national priority voucher

SanegeneBio raises $110m for RNAi, plus other financings

Pfizer makes first-line case for Tukysa in breast cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks